Page 88 - Looking Statement News Today

Newrange Intersects New High-Grade Gold Zone at Pamlico; Drills 12.47 g/t Au over 4.5 metres Newrange Gold Corp. is pleased to announce that continued Reverse Circulation drilling at the Pamlico Project in Nevada has discovered high-grade, oxide gold mineralization approximately 85 meters east of the Merritt Zone.  Hole P21-115, drilled at -60°, intersected several high-grade structures assaying up to 22.35 grams gold per metric tonne over 1.5 meters surrounded by lower grade halos, very simi...

TechnipFMC plc: TechnipFMC Awarded a Significant Integrated EPCI (iEPCI) Contract for the Development of North El Amriya and North Idku (NEA/NI) TechnipFMC (Paris:FTI) (NYSE:FTI) (ISIN:GB00BDSFG982) has been awarded a significant (1) integrated Engineering Procurement Construction and Installation (iEPCI) contract by NIpetco and PetroAmriya, two Joint Ventures between Energean and Egyptian Natural Gas Holding Company (EGAS) and Egyptian General Petroleum Corporation (EGPC) for a subsea tieback ...

(2) Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Kodiak Copper Corp. (TSXV: KDK) (the "Company" or "Kodiak") today reports drill results from five further holes at its ongoing fully funded exploration program at the 100% owned MPD copper-gold porphyry project. MPD is located near producing mines in the prolific Quesnel Trough in southern British Columbia, with excellent infrastructure and year-round accessibility from paved highways. Claudia Tornquist, President and CEO...

Today marks the listing and first day of trading of shares of Technip Energies, a leading engineering technology company, on compartment A of Euronext's regulated market in Paris (ticker: TE). The

KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib LENVIMA Plus... | February 16, 2021

KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib LENVIMA Plus Everolimus Significantly Improved PFS and Objective Response Rate Versus Sunitinib First Results From Pivotal CLEAR Study Presented at 2021 Genitourinary Cancers Symposium and Published in the New England Journal of Medicine … KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Deat...

Toronto, Ontario--(Newsfile Corp. - February 12, 2021) - Labrador Iron Mines Holdings Limited (OTC Pink: LBRMF) (the "Company") reports its financial results for the three and nine months ended December

Lysogene Secures €5 million in Non-Dilutive Financing Strengthened cash position with cash runway extended to Q2 2022 Regulatory News: Lysogene (FR0013233475 LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today it has secured a non-dilutive financing of €5 million from BRED in the form of a state-guaranteed loan (PGE). This financing extends the Companys cash runway until Q2 2022, compared to the end of Q4 2021 previously...

Posted on 461 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Kenneth C. Frazier, chairman and chief executive officer, will retire as CEO, effective June 30, 2021. Mr. Frazier will continue to serve on Merck’s board of directors as executive chairman, for a transition period to be determined by the board. The Merck board of directors has unanimously elected Robert M. Davis, Merck’s curr...

Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results Fourth-Quarter 2020 Worldwide Sales Were $12.5 Billion, an Increase of 5% Fourth-Quarter 2020 GAAP Loss per Share Was $0.83, Reflecting Charges Related to Acquisitions and Intangible Asset Impairments; Fourth-Quarter Non-GAAP EPS Was $1.32 Full-Year 2020 Worldwide Sales Were $48.0 Billion, an Increase of 2%; Excluding the Impact from Foreign Exchange, Sales Grew 4% KEYTRUDA 2020 Worldwide Sales Grew 30% to $14.4 … Fourth-Qua...